Amortization of Intangible Assets of Lineage Cell Therapeutics, Inc. from 31 Dec 2010 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Lineage Cell Therapeutics, Inc. quarterly and annual Amortization of Intangible Assets in USD history and change rate from 31 Dec 2010 to 31 Mar 2025.
  • Lineage Cell Therapeutics, Inc. Amortization of Intangible Assets for the quarter ending 31 Mar 2025 was $0, a 100% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. Amortization of Intangible Assets for the twelve months ending 31 Mar 2025 was $0, a 100% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2024 was $22,000, a 83% decline from 2023.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2023 was $130,000, a 10% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Amortization of Intangible Assets for 2022 was $145,000, a 31% decline from 2021.
Source SEC data
View on sec.gov
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Change (%)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Amortization of Intangible Assets (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $0 $0 -$22,000 -100% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $22,000 $0 -$32,000 -100% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
Q3 2024 $54,000 $0 -$33,000 -100% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $87,000 $0 -$32,000 -100% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $119,000 $22,000 -$11,000 -33% 01 Jan 2024 31 Mar 2024 10-Q 06 Nov 2025 2025 Q3
Q4 2023 $130,000 $32,000 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $33,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $32,000 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $33,000 +$5,000 +18% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q2 2022 $125,000 $32,000 -$1,000 -3% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $126,000 $28,000 -$84,000 -75% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $210,000 $32,000 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $33,000 -$217,000 -87% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $33,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $112,000 -$386,000 -78% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $250,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q1 2020 $498,000 +$13,000 +2.7% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q1 2019 $2,095,000 $485,000 -$97,000 -17% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,192,000 $410,000 -$137,000 -25% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $2,329,000 $600,000 $0 0% 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q2 2018 $2,329,000 $600,000 $0 0% 01 Apr 2018 30 Jun 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 $2,329,000 $582,000 -$20,000 -3.3% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $2,349,000 $547,000 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $600,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $600,000 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $602,000 -$712,000 -54% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q1 2016 $1,314,000 $0 0% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q1 2015 $1,314,000 -$53,998 -3.9% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q1 2014 $1,367,998 +$725,425 +113% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q1 2013 $642,573 +$106,836 +20% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q1 2012 $535,737 +$79,585 +17% 01 Jan 2012 31 Mar 2012 10-Q 10 May 2013 2013 Q1
Q1 2011 $456,152 01 Jan 2011 31 Mar 2011 10-Q 10 May 2012 2012 Q1

Lineage Cell Therapeutics, Inc. Annual Amortization of Intangible Assets (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $22,000 -$108,000 -83% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2025 2024 FY
2023 $130,000 -$15,000 -10% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $145,000 -$65,000 -31% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $210,000 -$1,006,000 -83% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $1,216,000 -$782,000 -39% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $1,998,000 -$194,000 -8.8% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $2,192,000 -$157,000 -6.7% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $2,349,000 -$1,228,000 -34% 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
2016 $3,577,000 -$1,679,000 -32% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2018 2017 FY
2015 $5,256,000 -$2,104,000 -29% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018 2017 FY
2014 $7,360,000 +$4,064,000 +123% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $3,296,000 +$849,025 +35% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $2,446,975 +$455,775 +23% 01 Jan 2012 31 Dec 2012 10-K 11 Mar 2015 2014 FY
2011 $1,991,200 +$1,201,083 +152% 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014 2013 FY
2010 $790,117 01 Jan 2010 31 Dec 2010 10-K 18 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.